ArticleClinical rheumatology2025
Utilization of disease activity scores and acute phase reactants in predicting colchicine response assessed by FMF50: a retrospective cohort study in children with Familial Mediterranean Fever.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMonitoring disease activity in Familial Mediterranean Fever (FMF) patients might be challenging, mainly due to accompanying inflammatory conditions. This study assessed disease activity and colchicine response in children with FMF, using Auto-Inflammatory Diseases Activity Index (AIDAI), Pras, Mor, International Severity Score for FMF (ISSF), and FMF50 scores, and examined their acute phase reactant (APR) predictive value for FMF50 response.
methodsFMF patients meeting Eurofever/PRINTO criteria and receiving colchicine for ≥ 6 months were included. Patients without exon 10 mutations and with poor adherence were excluded. Disease activity was assessed using AIDAI, Pras, Mor, and ISSF scores, while FMF50 evaluated treatment response. Concordance among activity scores was analyzed using Cohen's and Fleiss's Kappa. Patients were grouped as FMF50 responders or non-responders. Logistic regression identified FMF50 response predictors.
resultsA total of 117 pediatric FMF patients (44.4% female) were included. ISSF, AIDAI, and Pras scores were significantly higher in non-responders compared to responders (p < 0.001). Elevated CRP (OR 1.035, 95% CI 1.002-1.070, p < 0.05), ISSF (OR 1.703, 95% CI 1.135-2.557, p < 0.05), and AIDAI scores (OR 1.253, 95% CI 1.053-1.491, p < 0.05) at 3 months predicted FMF50 non-response at 6 months. Multivariate analysis identified high ISSF (OR 1.745, 95% CI 1.129-2.698, p < 0.05) and AIDAI scores (OR 1.265, 95% CI 1.056-1.514, p < 0.05) as independent predictors. APRs were correlated with ISSF, Pras, and AIDAI scores. Kappa analyses revealed poor agreement among activity scores (Kappa values 0.157 to - 0.048).
conclusionISSF, AIDAI scores, and CRP can predict FMF50 response three months in advance and recommend earlier evaluation of further therapies in non-responders. Key Points • This study is the only investigation in the literature that evaluates all disease activity scores and examines the correlations between these scores and APRs. • As the second study to utilize the FMF50 score in assessing colchicine response, it contributes significantly to the literature with a larger patient cohort. • Elevated CRP values, along with high ISSF and AIDAI scores at the third month, play a critical role in predicting the FMF50 response at the sixth month, indicating the necessity for early evaluation of advanced treatment options.
Indexed as
Identifiers
40659991What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.